The current status of immunobased therapies for metastatic renal-cell carcinoma.

IF 6.2 Q1 IMMUNOLOGY

ImmunoTargets and Therapy Pub Date : 2017-12-05 eCollection Date: 2017-01-01 DOI:10.2147/ITT.S134850

Niranjan J Sathianathen, Suprita Krishna, J Kyle Anderson, Christopher J Weight, Shilpa Gupta, Badrinath R Konety, Thomas S Griffith

引用次数: 0

Abstract

The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC.

Abstract Image

查看原文本刊更多论文

转移性肾细胞癌的免疫疗法现状。

转移性肾细胞癌（mRCC）的治疗是一项重要的临床挑战。自上世纪 90 年代初获得批准以来，特异性免疫疗法一直是治疗转移性肾细胞癌的主要手段，也是唯一能长期治愈转移性肾细胞癌的疗法。然而，近来特异性免疫疗法在治疗包括肾癌在内的多种恶性肿瘤领域取得了里程碑式的进展。本综述概述了目前可用于治疗 mRCC 的一系列免疫制剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ImmunoTargets and Therapy IMMUNOLOGY-

CiteScore

16.50

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Immuno Targets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered.In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.